Parthenon

Parthenon Therapeutics is a clinical-stage biotechnology company dedicated to developing a new class of therapies that target the tumor microenvironment to overcome immune exclusion. The company's primary focus is on neutralizing the mechanical and biological barriers, such as the collagen matrix, that prevent immune cells from infiltrating and attacking tumors. Their lead candidate, PRTH-101, is a first-in-class monoclonal antibody targeting Discoidin Domain Receptor 1 (DDR1), which is responsible for organizing the dense collagen barriers in many solid tumors. By breaking down these barriers, Parthenon aims to make 'cold' tumors 'hot' and improve the efficacy of existing immunotherapies. The company is headquartered in the biotech hub of Cambridge, Massachusetts, and is backed by a strong syndicate of life science investors.